Entelos said this week that Pfizer has taken a non-exclusive perpetual license to its Metabolism Physiolab platform.
Under the terms of the license, which expands on a previous agreement between the firms, Pfizer will have access to both Entelos’ PhysioLab Modeler software and its PhysioLab Simulation Server to study the biological mechanisms underlying disease.
Further details about the terms of the license were not disclosed.
The two companies announced a research partnership based on the Entelos Cardiovascular PhysioLab platform in 2007 following an earlier announcement that a subsidiary of Pfizer based in Ireland had agreed to purchase more than 2.5 million Entelos shares worth $1.5 million (BioInform 11/16/2007).
At the time of the original announcement, Entelos disclosed that the research would be focused on identifying biomarkers and interpreting clinical study data.